Pinealon

Pinealon (systematic name Glu-Asp-Arg, also designated EDR) is a synthetic tripeptide isolated from Cortexin, a polypeptide extract derived from the cerebral cortex that has been used clinically in Russia as a neuroprotective agent. Its molecular formula is C15H26N6O8, with a molar mass of approximately 418 g/mol, and its small size is central to the proposed mechanism.

The leading hypothesis advanced by Khavinson's research group is that EDR penetrates both cellular and nuclear membranes and binds directly to specific DNA promoter sequences, functioning as a transcriptional modulator rather than through conventional receptor-ligand signaling. Computational docking studies have identified candidate binding motifs in the promoter regions of TPH1 (tryptophan hydroxylase 1, the rate-limiting enzyme in serotonin synthesis), PPARA, PPARG, SOD2 (superoxide dismutase 2), GPX1 (glutathione peroxidase 1), CASP3 (caspase-3), and APOE.

• Antioxidant axis: EDR is reported to upregulate SOD2 and GPX1 in hypoxia-sensitive rat brain, reducing ROS accumulation in cerebellar neuron cultures. • Apoptotic axis: downregulation of caspase-3 and p53 expression has been reported in preclinical models. • MAPK/ERK signaling: EDR delays ERK1/2 activation under homocysteine-induced oxidative stress in cell culture. • Serotonin-melatonin axis: TPH1 promoter binding is proposed to increase tryptophan hydroxylase expression, augmenting serotonin synthesis; because serotonin is the direct precursor to melatonin in the pineal gland, this pathway offers a mechanistic rationale for effects on circadian regulation.

These mechanistic proposals are drawn entirely from the Khavinson group's computational modeling and cell culture experiments and have not been independently validated.

The published evidence base for Pinealon is narrow and originates almost exclusively from Vladimir Khavinson's group at the Saint Petersburg Institute of Bioregulation and Gerontology. No completed randomized, placebo-controlled human trials have been published in indexed English-language journals.

The most cited human data appears as a brief reference within a 2020 narrative review (Khavinson et al., Molecules, PMID 33396470): oral Pinealon at 0.2 mg twice daily was added to standard care in 72 patients with post-traumatic cerebrasthenia (ages 30-74) over 20-30 days. The authors report improved memory, reduced headache duration and intensity, improved emotional balance, and increased alpha-wave activity on EEG. No randomization, control group, or blinding is described; this observation functions as an uncontrolled open-label case series. The underlying primary study is not independently indexed or retrievable.

Preclinical data are more extensive. A 2012 rat study (Arutjunyan et al., Int J Clin Exp Med, PMID 22567179, n not specified) showed maternal Pinealon administration improved spatial learning and reduced cerebellar neuron ROS in offspring of dams exposed to prenatal hyperhomocysteinemia. A 2017 hippocampal neuron culture study (Kraskovskaya et al., Bull Exp Biol Med, PMID 28853087) reported EDR at 200 ng/mL increased mushroom-type dendritic spines by 71% in amyloid-exposed cultures, restoring them to near-normal levels. A 2021 in vivo mouse study (Khavinson et al., Pharmaceuticals, PMID 34071923) used 5xFAD transgenic Alzheimer's model mice treated with intraperitoneal EDR at 400 mcg/kg from age 2 to 4 months; EDR prevented mushroom spine elimination, with more pronounced effects in males than females.

The entire evidence base is generated by the compound's developers. Independent replication from outside Khavinson-affiliated laboratories is absent from the indexed literature.

Typical dosage: 10 mg (daily for cycles).

The only peer-reviewed human dosing reference is from a brief observation cited within Khavinson et al. (2020, PMID 33396470): oral Pinealon at 0.2 mg (200 mcg) twice daily for 20 to 30 days as adjunctive therapy in patients with post-traumatic cerebrasthenia. No pharmacokinetic data exists to confirm oral bioavailability of this tripeptide in humans.

In the 2021 transgenic mouse study (PMID 34071923), dosing was 400 mcg/kg administered intraperitoneally once daily over a two-month treatment window.

In compounding and community practice — where Pinealon is available as a research-grade lyophilized powder in vials of 5 to 20 mg — the following protocols are reported (not derived from clinical trials):

• Subcutaneous injection: 1 to 2 mg once daily, 10 to 30-day courses, with 3 to 6-month intervals between cycles; this mirrors the cycling model used across other Khavinson bioregulators. • Some practitioner sources describe 5 to 10 mg/day subcutaneously for more intensive protocols; this range lacks any clinical trial basis. • Oral and sublingual forms (1 to 5 mg) are also used, though intestinal hydrolysis of tripeptides and the consequent bioavailability for CNS access have not been established for this compound. • Administration is commonly timed 30 to 60 minutes before sleep when the goal is circadian or sleep-related support.

This information is provided for educational and research-reference purposes only and does not constitute medical advice. Pinealon is not approved by the FDA or EMA for any therapeutic indication and should not be self-administered without qualified medical supervision.

No compound-specific stability data has been identified for this peptide. The general lyophilized-peptide handling framework applies — see Storage & handling for temperature, reconstitution diluent, and beyond-use dating principles.

No published study has examined Pinealon in combination with any other agent. All combination use described below is anecdotal, drawn from community forums and practitioner summaries, and should be interpreted accordingly.

Pinealon plus Epithalon (Ala-Glu-Asp-Gly, a Khavinson tetrapeptide with proposed telomerase-activating properties) is the most commonly reported pairing. The anecdotal rationale is complementarity: Epithalon is directed at systemic cellular aging, while Pinealon targets neuronal gene expression specifically. Users typically run the two in coordinated 10 to 30-day cycles. No combination study exists.

Pinealon plus Semax (an ACTH 4-7 analog with reported BDNF-elevating properties) is described in community practice as combining an acute cognitive-enhancing agent (Semax) with a longer-term neuroprotective maintenance compound (Pinealon). The mechanistic rationale is plausible but entirely speculative; no combination data exist.

A commercial nasal spray preparation has combined Pinealon with DSIP (delta sleep-inducing peptide), leveraging the hypothesized sleep-modulatory properties of both. No clinical comparison or controlled data evaluating this combination are available.

All combination strategies described here are anecdotal. Interaction effects, additive or antagonistic pharmacodynamics, and combined safety profiles are unknown.

Pinealon is not currently FDA-approved for any indication. It is generally classified as a research compound. Regulatory status varies by country.

PeptideSciences101 does not endorse vendors. For transparency metrics and third-party testing notes, see the vendor directory.

Reported side effects: Minimal side effects

Pinealon has no dedicated published safety or toxicology studies in humans. There are no Phase I dose-escalation trials, no pharmacovigilance data, and no long-term human safety registry. The safety profile inferred from the Russian bioregulator literature is based on sparse open-label observations from the compound's developers and cannot be considered independently validated.

Reported adverse effects in community use and compounding practice are primarily injection-site reactions (redness, swelling, bruising) from subcutaneous administration. Additional non-specific effects mentioned in community reports include transient headache, mild fatigue, gastrointestinal discomfort, lightheadedness, and flushing. Allergic or hypersensitivity reactions are possible with any peptide compound.

Theoretical contraindications based on proposed mechanism:

• Active or prior malignancy: EDR modulates caspase-3 and p53 expression, both of which are central to apoptotic regulation in tumor biology; the clinical significance is unknown but warrants caution. • Pregnancy and lactation: no human or animal reproductive safety data have been published. • Hypersensitivity to any component of the formulation.

Regulatory status: Pinealon is not approved by the US FDA, the European Medicines Agency, or equivalent regulatory bodies in Western jurisdictions. It is classified as a research compound and is not authorized for therapeutic use outside of properly constituted clinical trials. Products sold as "research-grade" peptides are not subject to pharmaceutical manufacturing quality controls, introducing additional risks of impurity and incorrect concentration. The true adverse event profile of Pinealon in humans remains essentially unknown.